Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.
2.

Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.

Shiffman ML.

Curr Gastroenterol Rep. 2006 Feb;8(1):46-52. Review.

PMID:
16510034
3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

4.
5.

The evolving treatment of chronic hepatitis C: where we stand a decade out.

Saadeh S, Davis GL.

Cleve Clin J Med. 2004 May;71 Suppl 3:S3-7. Review.

PMID:
15468610
7.

Chronic hepatitis C: management of treatment failures.

Keeffe EB.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S102-5. Review.

PMID:
16234055
8.

[Treatment of hepatitis C virus infection].

Zeuzem S.

Praxis (Bern 1994). 2005 May 4;94(18):721-6. Review. German.

PMID:
15938383
9.

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.

del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA.

AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3.

PMID:
18453851
10.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
11.

Response-guided therapy: optimizing treatment now and in the future.

Marcellin P, Rizzetto M.

Antivir Ther. 2008;13 Suppl 1:1-2. No abstract available.

PMID:
18432156
12.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

13.

Management of patients with chronic hepatitis C virus infection and previous nonresponse.

Shiffman ML.

Rev Gastroenterol Disord. 2004;4 Suppl 1:S22-30. Review.

PMID:
15184821
14.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
15.

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.

Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D.

Liver Int. 2007 Sep;27(7):954-9.

PMID:
17696934
16.

Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.

Abdo AA, Sanai FM.

Ann Saudi Med. 2009 Jan-Feb;29(1):1-3. No abstract available.

17.

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.

Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O.

Scand J Gastroenterol. 2007 Feb;42(2):247-55.

PMID:
17327945
18.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

19.
20.

Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Salmerón J, De Rueda PM, Ruiz-Extremera A, Casado J, Huertas C, Bernal Mdel C, Rodríguez L, Palacios A.

Dig Dis Sci. 2006 May;51(5):960-7.

PMID:
16758308

Supplemental Content

Support Center